Spain
Trilingual Medical Leader | MBA in Innovation Management | Oncology, & Clinical Safety Expert Medical doctor with 5+ years driving therapeutic innovation across LATAM markets at multinational pharmaceutical companies including MSD-Merck (US & CAN), Johnson & Johnson, and Hetero Group. Specialized in oncology portfolio management, clinical safety, pharmacovigilance, and evidence-based adoption of novel therapies. Leadership & Regional Impact Currently serving as Medical Manager at Seven Pharma (Hetero Group), leading Colombia's largest oncology portfolio (32+ medications) with expanded regional responsibilities across Colombia, Brazil, and Mexico. Proven track record managing cross-cultural teams in LATAM and Asia, including international assignment in India coordinating regional medical strategies. Core Expertise Oncology Medical Affairs & Portfolio Strategy Clinical Safety & Pharmacovigilance (Phase II–IV trials) Regulatory Compliance & Medical Education Cross-functional Leadership (Sales, Marketing, Regulatory) AI-driven innovation in Medical and Scientific Affairs I lead with empathy, building high-performing multidisciplinary teams through collaborative decision-making and continuous development. My trilingual capabilities (Spanish, English, Portuguese) enable strategic partnerships and scientific excellence across diverse cultural contexts. During my tenure at Johnson & Johnson, I contributed to the design and implementation of AI use cases applied to Medical and Scientific Affairs operations, reinforcing my commitment to innovation-driven medical leadership.
Built the Medical and Scientific Affairs function from the ground up, establishing the operational, strategic, and scientific infrastructure for one of Colombia's most comprehensive specialty portfolios — spanning Oncology, Hematologic Malignancies, Virology, and Specialty Care, with 30+ FDA-approved and WHO-prequalified medications. Key Achievements: Designed and implemented the Medical Affairs structure from scratch, including CRM system, SOPs, scientific material coding framework, and MSL field operations model for a 2-person medical team. Led the medical strategy for 10+ first-generic launches, including sugammadex and sacubitril/valsartan,dolutegravir positioning each product through evidence-based scientific differentiation in a competitive generics market. Engaged 60+ KOLs across Colombia, including regional and internationally recognized specialists in oncology, hematology, and virology, building a structured scientific network aligned with portfolio priorities. Developed 30+ scientific and medico-marketing materials with rigorous scientific approach, fully compliant with Colombian pharmaceutical regulations (INVIMA). Assumed expanded regional responsibilities across Colombia, Brazil, and Mexico — formally assigned by HQ — leading medical training programs, reviewing regional materials, and developing scientific slide decks for LATAM markets over a 5-month period. Serves concurrently as Local Pharmacovigilance Officer, ensuring full regulatory compliance and safety reporting standards across the entire portfolio.
Regional Medical Manager LATAM (International Assignment) | Hetero Group HQ Jul. 2025 – Sept. 2025 | Hyderabad, Telangana, India Selected for international assignment at Hetero Group's global headquarters in Hyderabad, India, to lead the medical launch strategy for lenacapavir in emerging markets — a first-in-class HIV capsid inhibitor for which Hetero holds manufacturing, sales, and distribution licensing rights across emerging market territories. Key Contributions: Designed and executed the medical launch strategy for lenacapavir across emerging markets, including scientific positioning, evidence synthesis, and market-specific medical differentiation. Led training programs for the global medical team, building scientific capabilities around lenacapavir's mechanism of action, clinical evidence, and therapeutic positioning. Participated in high-level strategic meetings with regional and global medical leadership to align launch priorities across markets. Coordinated cross-cultural medical affairs activities across LATAM and global teams from HQ, reinforcing regional scientific standards and launch readiness.
Regional Scientific Coordinator LATAM | Johnson & Johnson Innovative Medicine Jul. 2023 – Jul. 2024 | LATAM Region Served as the senior Scientific Affairs field role across the full Latin American region — spanning Mexico to Argentina and Chile — managing the scientific strategy for a high-impact oncology and specialty portfolio including apalutamide (GU Oncology), macitentan and selexipag (Pulmonary Arterial Hypertension), and respiratory syncytial virus therapeutics (ID-V). Key Contributions: Led regional KOL engagement strategy across LATAM, building and maintaining relationships with Tier 1 urology oncology specialists, including direct scientific engagement and coordination with Dr. Neal Shore (globally recognized GU oncology KOL, USA). Represented Johnson & Johnson Innovative Medicine at the American Urological Association (AUA) Annual Meeting as official J&J staff, and led exclusive J&J scientific events with regional LATAM KOLs. Designed and facilitated multiple confidential Advisory Boards across therapeutic areas, contributing to their scientific structure, agenda, and strategic outcomes. Contributed to Market Access and Real-World Evidence generation projects, bridging medical and scientific insights with portfolio access strategies across LATAM markets. Pioneered AI use case initiatives applied to Medical and Scientific Affairs operations, positioning the function at the forefront of innovation-driven medical leadership within J&J LATAM. Operated across all LATAM clusters with cross-cultural scientific communication in Spanish, English, and Portuguese.
R&D Unit Leader | CELAGEM Sept. 2022 – Jul. 2023 | Bogotá, Colombia Led the creation and structuring of the Research & Development function at CELAGEM, a leading assisted reproduction and fertility clinic, applying a rigorous scientific and process-improvement framework informed by MBA-level strategic management principles. Key Contributions: Conducted an in-depth immersion in reproductive medicine and fertility science to build the technical foundation required to lead evidence generation initiatives in a highly specialized clinical environment. Authored the institution's first formal research protocol, establishing the scientific and methodological standards for internal evidence generation. Defined and implemented the clinical area's KPI framework from scratch, creating measurable performance indicators across scientific and operational dimensions. Drove process improvements that enhanced the efficiency and clinical effectiveness of patient care operations. Contributed to positioning CELAGEM's clinical function toward a data-driven, evidence-based organizational model.
Clinical Safety Scientist → Sr Medical Safety Reviewer | MSD (Merck) Jun. 2018 – Aug. 2022 | Global (Remote/Colombia) Progressed through three successive roles within MSD's Global Clinical Safety function, contributing to the safety surveillance and regulatory management of one of the most impactful oncology pipelines in the industry — the KEYNOTE pembrolizumab program across Phase II, III, and IV trials. Key Contributions: Managed safety oversight for up to 20 concurrent KEYNOTE clinical protocols, covering immuno-oncology indications across multiple tumor types and patient populations. Authored and reviewed Individual Case Safety Reports (ICSRs) and clinical narratives, ensuring accuracy, regulatory compliance, and timely submission to global health authorities. Collaborated directly with global safety teams in the US and Europe, operating within MSD's international clinical safety governance framework. Participated in Safety Review Boards, contributing to benefit-risk evaluations and safety signal detection across active clinical programs. Engaged directly with FDA and EMA in regulatory safety processes, gaining firsthand experience in the standards and expectations of the two primary global regulatory authorities. Promoted to Sr Medical Safety Reviewer in recognition of performance and scientific contribution to the global safety function.
Consulta Compartida de ortopedia general . y sub esepecialidades , pediatrica, rodilla , pie , hombro y mano.